Corbus Logo.jpg
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
March 12, 2024 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
Encouraging CRB-701 (SYS6002) First-in-Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 IND Application for CRB-601 cleared; Ph1...
Corbus Logo.jpg
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
March 06, 2024 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...
Corbus Logo.jpg
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
February 28, 2024 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today...
Corbus Logo.jpg
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024 09:50 ET | Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...
Corbus Logo.jpg
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
February 02, 2024 16:01 ET | Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today...
Corbus Logo.jpg
Corbus Pharmaceuticals Announces Pricing of Public Offering
January 31, 2024 09:19 ET | Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today...
Corbus Logo.jpg
Corbus Pharmaceuticals Announces Proposed Public Offering
January 30, 2024 18:55 ET | Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today...
Corbus Logo.jpg
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
January 26, 2024 07:30 ET | Corbus Pharmaceuticals Holdings, Inc.
Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant dosesAll assessable nectin-4 positive study participants with mUC and cervical cancer treated...
Corbus Logo.jpg
Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
January 23, 2024 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today that the abstract for the first-in-human Phase 1...
Corbus Logo.jpg
Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
January 09, 2024 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
CRB-601 is designed to block the activation of latent TGFβ in the tumor microenvironmentPhase 1 clinical study set to commence H1 2024Pre-clinical data presented demonstrates robust anti-tumor...